Chronic Lower Back Pain NDA Approvals, Emerging Drugs, and Pipeline Insight Report 2023 | Key Companies- Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, and Others

DelveInsight's, "Chronic Lower Back Pain Pipeline Insight 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Chronic Lower Back Pain pipeline landscape. It covers the Chronic Lower Back Pain pipeline drug profiles, including Chronic Lower Back Pain clinical trials and nonclinical stage products. It also covers the Chronic Lower Back Pain therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Lower Back Pain Pipeline Report

• DelveInsight's Chronic Lower Back Pain pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Chronic Lower Back Pain treatment.

• The leading Chronic Lower Back Pain Companies include Mesoblast, Eli Lilly and Company Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others

• Promising Chronic Lower Back Pain Pipeline Therapies include buprenorphine, Duloxetine, Bicifadine, Oxycodone DETERx, OROS hydromorphone, Hydrocodone bitartrate q24h film-coated tablets, and others

• The Chronic Lower Back Pain companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lower Back Pain R&D. The Chronic Lower Back Pain therapies under development are focused on novel approaches to treat/improve Chronic Lower Back Pain.

To explore more information on the latest breakthroughs in the Chronic Lower Back Pain Pipeline treatment landscape of the report, click here @ Chronic Lower Back Pain Pipeline Outlook- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Lower Back Pain Overview
Low back pain that has been present for longer than three months is considered as chronic, although there is still no consensus about the definition of Chronic Lower Back Pain (CLBP). 5-10% of all low back pain patients will develop CLBP. Chronic low back pain (CLBP) has been associated with neurochemical, structural, and functional cortical changes of several brain regions including the somatosensory cortex.

Chronic Lower Back Pain Emerging Drugs Profile

• MPC-06-ID: Mesoblast
MPC-06-ID is a tier 1 product candidate which consists of a unit dose of 6 million mesenchymal precursor cells (MPCs). It is injected by syringe directly into a targeted damaged disc in an outpatient procedure. MPC-06-ID is a Phase III product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections and have no further treatment option other than invasive and costly surgical interventions.

• PP353: Persica Pharmaceuticals
PP353 is a unique combination of an antibiotic, a radio-opaque dye and a thermosensitive gel that provides a product for intradiscal injection. It is currently being studied in Phase I/II developmental studies for the treatment of patients with Chronic Low Back Pain associated with verterbral body endplate bone oedema.

Request a sample and discover the recent advances in Chronic Lower Back Pain Ongoing Clinical Trial Analysis and Medications, click here @ Chronic Lower Back Pain Treatment Landscape- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Lower Back Pain Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Chronic Lower Back Pain. The companies which have their Chronic Lower Back Pain drug candidates in the most advanced stage, i.e. Phase III include, Mesoblast.

Chronic Lower Back Pain Pipeline Segmentation

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic Lower Back Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

For further information, refer to the detailed Chronic Lower Back Pain Unmet Needs, Chronic Lower Back Pain Market Drivers, and Barriers, click here for Chronic Lower Back Pain Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Lower Back Pain Pipeline Report

• Coverage- Global

• Chronic Lower Back Pain Companies- Mesoblast, Eli Lilly and Company Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others

• Chronic Lower Back Pain Pipeline Therapies- buprenorphine, Duloxetine, Bicifadine, Oxycodone DETERx, OROS hydromorphone, Hydrocodone bitartrate q24h film-coated tablets, and others

• Chronic Lower Back Pain Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Chronic Lower Back Pain Market Drivers and Chronic Lower Back Pain Market Barriers, click here @ Chronic Lower Back Pain Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chronic Lower Back Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Lower Back Pain - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Chronic Lower Back Pain Collaboration Deals
9. MPC-06-ID: Mesoblast
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. LY3016859: Eli Lilly and Company
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I/II)
15. PP353: Persica Pharmaceuticals
16. Drug profiles in the detailed report…..
17. Preclinical and Discovery Stage Products
18. Drug name: Company name
19. Drug profiles in the detailed report…..
20. Chronic Lower Back Pain Key Companies
21. Chronic Lower Back Pain Key Products
22. Chronic Lower Back Pain- Unmet Needs
23. Chronic Lower Back Pain- Market Drivers and Barriers
24. Chronic Lower Back Pain- Future Perspectives and Conclusion
25. Chronic Lower Back Pain Analyst Views
26. Chronic Lower Back Pain Key Companies
27. Appendix

Got Queries? Find out the related information on Chronic Lower Back Pain Mergers and acquisitions, Chronic Lower Back Pain licensing activities @ Chronic Lower Back Pain Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91 9568243403
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.